Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer

Authors: Ana E. Zacapala-Gómez, Napoleón Navarro-Tito, Luz del C. Alarcón-Romero, Carlos Ortuño-Pineda, Berenice Illades-Aguiar, Eduardo Castañeda-Saucedo, Julio Ortiz-Ortiz, Olga L. Garibay-Cerdenares, Marco A. Jiménez-López, Miguel A. Mendoza-Catalán

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Cervical cancer (CC) is the fourth cause of mortality by neoplasia in women worldwide. The use of immunomarkers is an alternative tool to complement currently used algorithms for detection of cancer, and to improve selection of therapeutic schemes. Aberrant expression of Ezrin and E-cadherin play an important role in tumor invasion. In this study we analyzed Ezrin and E-cadherin expression in liquid-based cervical cytology samples, and evaluated their potential use as prognostic immunomarkers.

Methods

Immunocytochemical staining of Ezrin and E-cadherin was performed in cervical samples of 125 patients. The cytological or histological diagnostic was performed by Papanicolaou staining or H&E staining, respectively. HPV genotyping was determined using INNO-LIPA Genotyping Extra kit and the HPV physical status by in situ hybridization. Ezrin expression in HaCaT, HeLa and SiHa cell lines was determined by immunocytochemistry, immunofluorescence and Western blot.

Results

High Ezrin expression was observed in cervical cancer samples (70%), samples with multiple infection by HR-HPV (43%), and samples with integrated viral genome (47%). High Ezrin expression was associated with degree of SIL, viral genotype and physical status. In contrast, low E-cadherin expression was found in cervical cancer samples (95%), samples with multiple infection by HR-HPV/LR-HPV (87%) and integrated viral genome (72%). Low E-cadherin expression was associated with degree of SIL and viral genotype. Interestingly, Ezrin nuclear staining was associated with degree of SIL and viral genotype. High Ezrin expression, high percent of nuclear Ezrin and low E-cadherin expression behaved as risk factors for progression to HSIL and cervical cancer.

Conclusions

Ezrin and E-cadherin expression profile in cervical cytology samples could be a potential prognostic marker, useful for identifying cervical lesions with a high-risk of progression to cervical cancer.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef
2.
3.
Evans MF, Mount SL, Beatty BG, Cooper K. Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol. 2002;15(12):1339–47.CrossRefPubMed
4.
Sari Aslani F, Safaei A, Pourjabali M, Momtahan M. Evaluation of Ki67, p16 and CK17 markers in differentiating cervical intraepithelial neoplasia and benign lesions. Iran J Med Sci. 2013;38:15–21.PubMedPubMedCentral
5.
Zubillaga-Guerrero MI, Illades-Aguiar B, Leyva-Vazquez MA, Flores-Alfaro E, Castañeda-Saucedo E, Muñoz-Valle JF, et al. The integration of HR-HPV increases the expression of cyclins a and E in cytologies with and without low-grade lesions. J Cytol. 2013;30(1):1–7.CrossRefPubMedPubMedCentral
6.
Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol. 2011;135(2):212–20.CrossRefPubMed
7.
Vega-Peña A, Illades-Aguiar B, Flores-Alfaro E, López-Bayghen E, Leyva-Vázquez MA, Castañeda-Saucedo E, et al. Risk of progression of early cervical lesions is associated with integration and persistence of HPV-16 and expression of E6, Ki-67, and telomerase. J Cytol. 2013;30(4):226–32.CrossRefPubMedPubMedCentral
8.
Pinto AP, Degen M, Villa LL, Cibas ES. Immunomarkers in gynecologic cytology: the search for the ideal “biomolecular Papanicolaou test”. Acta Cytol. 2012;56(2):109–21.CrossRefPubMed
9.
Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adhes Migr. 2011;5(2):199–206.CrossRef
10.
11.
Bartova M, Hlavaty J, Tan Y, Singer C, Pohlodek K, Luha J, Walter I. Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases. Clin Exp Metastasis. 2017;34(5):333–44.CrossRefPubMed
12.
Valdman A, Fang X, Pang ST, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol. 2005;48(5):852–7.CrossRefPubMed
13.
Bakheet AMH, Mahmoud SA, Huang Y, Zhang J, Wang J, Wei Y, et al. Ezrin as a possible diagnostic and/or prognostic biomarker in mice lymphatic metastatic hepatocellular carcinoma in vivo. Biofactors. 2017;43(5):662–72.CrossRefPubMed
14.
Fadiel A, Chen Z, Ulukus E, Ohtani K, Hatami M, Naftolin F. Ezrin overexpression by transformed human ovarian surface epithelial cells, ovarian cleft cells, and serous ovarian adenocarcinoma cells. Reprod Sci. 2012;19(8):797–805.CrossRefPubMed
15.
Köbel M, Langhammer T, Hüttelmaier S, Schmitt WD, Kriese K, Dittmer J, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol. 2006;19(4):581–7.CrossRefPubMed
16.
Auvinen E, Carpen O, Korpela T, Ronty M, Vaheri A, Tarkkanen J. Altered expression of ezrin, E-cadherin and β-catenin in cervical neoplasia. Neoplasma. 2013;60(1):56–61.CrossRefPubMed
17.
Kong J, Li Y, Liu S, Jin H, Shang Y, Quan C, et al. High expression of ezrin predicts poor prognosis in uterine cervical cancer. BMC Cancer. 2013;13(1):520.CrossRefPubMedPubMedCentral
18.
Fadiel A, Choi SD, Park B, Kim TH, Buldo-Licciardi J, Ahmadi M, et al. Expression of Ezrin and estrogen receptors during cervical carcinogenesis. Reprod Sci. 2016;24(5):706–12.CrossRefPubMed
19.
Li M, Feng YM, Fang SQ. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017;50(4):1–9.
20.
Kong J, Di C, Piao J, Sun J, Han L, Chen L, et al. Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget. 2016;7(15):19631–42.CrossRefPubMedPubMedCentral
21.
Higashi K, Ueda Y, Shimasaki M, Ishigaki Y, Nakamura Y, Oguchi M, et al. High FDG uptake on PET is associated with negative cell-to-cell adhesion molecule E-cadherin expression in lung adenocarcinoma. Ann Nucl Med. 2017;31(8):590–5.CrossRefPubMed
22.
Zhao P, Guo S, Tu Z, Di L, Zha X, Zhou H, et al. Grhl3 induces human epithelial tumor cell migration and invasion via downregulation of E-cadherin. Acta Biochim Biophys Sin Shanghai. 2016;48(3):266–74.CrossRefPubMedPubMedCentral
23.
Zhang Z, Bu X, Chen H, Wang Q, Sha W. Bmi-1 promotes the invasion and migration of colon cancer stem cells through the downregulation of E-cadherin. Int J Mol Med. 2016;38(4):1199–207.CrossRefPubMedPubMedCentral
24.
Li B, Shi H, Wang F, Hong D, Lv W, Xie X, et al. Expression of E-, P- and n-cadherin and its clinical significance in cervical squamous cell carcinoma and precancerous lesions. PLoS One. 2016;11(5):1–13.
25.
26.
Tan J, Zhang C, Qian J. Expression and significance of Six1 and Ezrin in cervical cancer tissue. Tumour Biol. 2011;32(6):1241–7.CrossRefPubMed
27.
Shen ZY, Xu LY, Chen MH, Li EM, Li JT, Wu XY, et al. Upregulated expression of Ezrin and invasive phenotype in malignantly transformed esophageal epithelial cells. World J Gastroenterol. 2003;9(6):1182–6.CrossRefPubMedPubMedCentral
28.
Xu H, Pirisi L, Creek KE. Six1 overexpression at early stages of HPV16-mediated transformation of human keratinocytes promotes differentiation resistance and EMT. Virology. 2015;474:144–53.CrossRefPubMed
29.
Sun SH, Liu D, Deng YT, Zhang XX, Wan DY, Xi BX, et al. SIX1 coordinates with TGFβ signals to induce epithelial-mesenchymal transition in cervical cancer. Oncol Lett. 2016;12(2):1271–8.CrossRefPubMedPubMedCentral
30.
Halon A, Donizy P, Surowiak P, Matkowski R. ERM/rho protein expression in ductal breast cancer: a 15 year follow-up. Cell Oncol. 2013;36(3):181–90.CrossRef
Metadata
Title
Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer
Authors
Ana E. Zacapala-Gómez
Napoleón Navarro-Tito
Luz del C. Alarcón-Romero
Carlos Ortuño-Pineda
Berenice Illades-Aguiar
Eduardo Castañeda-Saucedo
Julio Ortiz-Ortiz
Olga L. Garibay-Cerdenares
Marco A. Jiménez-López
Miguel A. Mendoza-Catalán
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4243-7

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Symptomatic venous thromboembolism associated with peripherally inserted central catheters predicts a worse survival in nasopharyngeal carcinoma: results of a large cohort, propensity score–matched analysis

Research article

Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells

Research article

Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study

Research article

Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand

Research article

Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases

Research article

Activated innate lymphoid cell populations accumulate in human tumour tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits